ATAI
demonstrated a rapid and dose dependent effect along with a safety profile target engagement demonstrated safe well tolerated sedation comparable to placebo phase study trial design results summary | ATAI
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
32 of 34
Similar slides by ATAI
See diffirences between slides (animation)
Investor Presentation
October 2023
demonstrated a rapid and dose dependent effect along with a safety profile phase study trial design results summary | ATAI
Related slides by other companies
MAIA Biotechnology
Investor Presentation
October 2023
thio trial planned a | MAIA Biotechnology
MAIA Biotechnology
Investor Presentation
November 2023
thio trial planned a | MAIA Biotechnology
RayzeBio
IPO
September 2023
phase trial in first line combination treatment of | RayzeBio
BenevolentAI
Investor Presentation
October 2022
ben oral peripherally restricted inhibitor under development as a in class treatment for refractory ulcerative colitis an opportunity to differentiate on safety and a precision medicine approaches safety | BenevolentAI
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Investor Presentation
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io